Taletrectinib is another next-generation, CNS-penetrant ROS1/TRK inhibitor with a recent FDA breakthrough therapy designation for locally advanced or metastatic ROS1-mutated NSCLC [145]. Here, NTRK1 is linked to non-small cell lung carcinoma.